Highly Potent Drugs

Sep 01, 2011
Pharmaceutical Technology Europe
By Pharmaceutical Technology Editors
Highly potent APIs (HPAPIs) represent a growing area of interest for the pharma industry. Mark Griffiths, CEO of Carbogen Amcis AG, explains why.
Sep 01, 2011
Pharmaceutical Technology
By Pharmaceutical Technology Editors
A Q&A with Joe Cascone, director of potent pharmaceutical development at Metrics, moderated by Patricia Van Arnum. Discussion of the key considerations made in facility design, equipment selection, and operations to achieve desired levels of containment.
Jul 01, 2011
By Pharmaceutical Technology Editors
A technical leader in solid dosage forms Pfizer CentreSource provides analytical, technical, regulatory, developmental, manufacturing and packaging support that spans the specialized realm of highly potent solid oral dose drug products.
Jun 03, 2011
Pharmaceutical Technology Europe
By Pharmaceutical Technology Editors
Effective containment in API and drug-product manufacturing encompasses a variety of process, equipment, and operational issues.
Jun 02, 2011
Pharmaceutical Technology
By Pharmaceutical Technology Editors
Effective containment in API and drug-product manufacturing encompasses a variety of process, equipment, and operational issues.
Apr 01, 2011
Pharmaceutical Technology Europe
By Pharmaceutical Technology Editors
The main challenge for tablet manufacturers processing highly potent APIs (HPAPIs) is to protect equipment operators from the inhalation of airborne particles and prevent skin contact with the product during the entire production process: dispensing, granulation, tablet compression, coating and packaging.
Jan 14, 2011
By Pharmaceutical Technology Editors
Dishman is giving a step further in its strategy to manufacture high potency (HiPo) Active Pharmaceutical Ingredients (APIs).
Oct 02, 2010
Pharmaceutical Technology
By Pharmaceutical Technology Editors
A recently released industry guide outlines a science- and risk-based approach to control the risk of cross-contamination.
Sep 15, 2010
Equipment and Processing Report
By Pharmaceutical Technology Editors
US Pharmacopeia apparatuses for testing the dissolution of transdermal drugs produce good, reproducible results. Yet some scientists believe that further modifications could improve the instruments? suitability for this application.
Sep 01, 2010
Pharmaceutical Technology Europe
The main advantage of outsourcing highly potent API (HPAPI) manufacture is that it eliminates the need to invest in expensive containment infrastructure, which can also be complex to engineer, install and maintain.
native1_300x100
lorem ipsum